Medine.co.uk

Linezolid 2 Mg/Ml Solution For Infusion

Informations for option: Linezolid 2 Mg/Ml Solution For Infusion, show other option
Document: leaflet MAH GENERIC_PL 24598-0046 change

Package leaflet: Information for the user

Linezolid 2mg/ml solution for infusion

Linezolid

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor, pharmacistor nurse.

This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1.    What Linezolid is and what it is used for

2.    What you need to know before you use Linezolid

3.    Howto use Linezolid

4.    Possible side effects

5.    Howto store Linezolid

6.    Contents of the pack and other information

1.    What Linezolid is and what it is used for

Linezolid is an antibiotic of the oxazolidinones group that works by stopping the growth of certain bacteria (germs) that cause infections. It is used to treat pneumonia and some infections in the skin or under the skin. Your doctor will have decided if Linezolid is suitable to treat your infection.

2.    What you need to know before you use Linezolid Do not use Linezolid:

if you are allergic to linezolid or any of the other ingredients of this medicine (listed in section 6).

if you are taking or have taken within the last 2 weeks any medicines known as monoamine oxidase inhibitors (MAOIs for example phenelzine, isocarboxazid, selegiline, moclobemide). These may be used to treat depression or Parkinson’s disease;

if you are breastfeeding. This is because it passes into breast milk and could affect the baby.

Warnings and precautions

Linezolid may not be suitable for you if you answer yes to any of the following questions. In this case tell your doctor as he/she will need to check your general health and your blood pressure before and during your treatment or may decide that another treatment is better for you.

Ask your doctor if you are not sure whether these categories apply to you.

•    Do you have high blood pressure, whether or not you are taking medicines for this?

•    Have you been diagnosed with an overactive thyroid?

•    Do you have a tumour of the adrenal glands (phaeochromocytoma) or carcinoid syndrome (caused by tumours of the hormone system with symptoms of diarrhoea, flushing of the skin, wheezing)?

•    Do you suffer from manic depression, schizoaffective disorder, mental confusion or other mental problems?

•    Are you taking any of the following medicines?

decongestant, cold or flu remedies containing pseudoephedrine or phenylpropanolamine

medicines used to treat asthma such as salbutamol, terbutaline, fenoterol antidepressants known as tricyclics or SSRIs (selective serotonin reuptake inhibitors) for example amitriptyline, cipramil, clomipramine, dosulepin, doxepin, fluoxetine, fluvoxamine, imipramine, lofepramine, paroxetine; sertraline medicines used to treat migraine such as sumatriptan and zolmitriptan medicines used to treat sudden, severe allergic reactions such as adrenaline (epinephrine)

medicines which increase your blood pressure, such as noradrenaline

(norepinephrine), dopamine and dobutamine

used to treat moderate to severe pain, such as pethidine

medicines used to treat anxiety disorders, such as buspirone

an antibiotic called rifampicin

Take special care with Linezolid

Tell your doctor before you are treated with this medicine if you:

•    bruise and bleed easily

•    are anaemic

•    are prone to getting infections

•    have a history of seizures

•    have liver problems or kidney problems particularly if you have dialysis

•    have diarrhoea

Tell your doctor immediately if during treatment you suffer from

•    problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or if your field of vision becomes restricted.

•    recurrent nausea or vomiting, abdominal pain or over breathing

You may develop diarrhoea while taking or after taking antibiotics, including Linezolid. If this becomes severe or persistent or you notice that your stool contains blood or mucus, you should stop taking Linezolid immediately and consult your doctor. In this situation, you should not take medicines that stop or slow bowel movement.

Other medicines and Linezolid

There is a risk that Linezolid may sometimes interact with certain other medicines to cause side effects such as changes in blood pressure, temperature or heart rate.

Tell your doctor if you are taking or have taken within the last 2 weeks the following medicines as Linezolid must not be taken if you are already taking these medicines or have taken them recently. (See also Section 2 above ‘Do not take Linezolid).’

•    monoamine oxidase inhibitors ( MAOIs for example phenelzine, isocarboxazid, selegiline, moclobemide). These may be used to treat depression or Parkinson’s disease

Also tell your doctor if you are taking the following medicines. Your doctor may still decide to give you Linezolid, but will need to check your general health and your blood pressure

before and during your treatment. In other cases, your doctor may decide that another treatment is better for you.

•    Decongestant cold or flu remedies containing pseudoephedrine or phenylpropanolamine.

•    Some medicines used to treat asthma such as salbutamol, terbutaline, fenoterol.

•    Certain antidepressants known as tricyclics or SSRIs (selective serotonin reuptake inhibitors). There are many of these, including amitriptyline, cipramil, clomipramine, dosulepin, doxepin, fluoxetine, fluvoxamine, imipramine, lofepramine, paroxetine, sertraline.

•    Medicines used to treat migraine such as sumatriptan and zolmitriptan.

•    Medicines used to treat sudden, severe allergic reactions such as adrenaline (epinephrine).

•    Medicines which increase your blood pressure, such as noradrenaline (norepinephrine), dopamine and dobutamine

•    Medicines used to treat moderate to severe pain, such as pethidine.

•    Medicines used to treat anxiety disorders, such as buspirone.

•    Medicines that stop blood clotting, such as warfarin.

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Linezolid with food, drink and alcohol

•    You can take Linezolid either before, during or after a meal.

•    Avoid eating large amounts of mature cheese, yeast extracts, or soya bean extracts (e.g. soy sauce) and drinking alcohol, especially draught beers and wine. This is because this medicine may react with a substance called tyramine which is naturally present in some foods to cause an increase in your blood pressure.

•    If you develop a throbbing headache after eating or drinking, tell your doctor or pharmacist immediately.

Pregnancy, breast-feeding and fertility

The effect of Linezolid in pregnant women is not known. Therefore it should not be taken in pregnancy unless advised by your doctor. Tell your doctor if you are pregnant, think you may be pregnant or are trying to become pregnant. You should not breastfeed when taking Linezolid because it passes into breast milk and could affect the baby.lt is not known whether Linezolid has an impact on human fertility.

Driving and using machines

Linezolid may make you feel dizzy or experience problems with your vision. If this happens, do not drive or operate any machinery. Remember that if you are unwell your ability to drive or operate machinery may be affected.

Important information about some of the ingredients in Linezolid

Linezolid contains glucose and sodium

Each 1 ml of Linezolid solution contains 45.7 mg glucose (13.7 g glucose in one bottle). Please tell your doctor or nurse if you are diabetic.

Each 1 ml of Linezolid solution contains 0.38 mg sodium (114 mg sodium in one bottle). Please tell your doctor or nurse if you are on a low sodium diet.

3. How to use Linezolid

This medicine will be given to you through a drip (by infusion into a vein) by a doctor or healthcare professional. The usual dose for adults (18 years and older) is 300 ml (600 mg linezolid) twice daily which is given directly into the blood stream (intravenously) by a drip over a period of 30 to 120 minutes. If you are on kidney dialysis, you should be given Linezolid after dialysis. A course of treatment usually lasts 10 to 14 days, but can last up to 28 days. The safety and effectiveness of this medicine have not been established for treatment periods longer than 28 days. Your doctor will decide how long you should be treated. While you are taking Linezolid, your doctor should perform regular blood tests to monitor your blood count. Your doctor should monitor your eyesight if you take Linezolid for more than 28 days.

Use in children and adolescents

Linezolid is not normally used to treat children and adolescents (under 18 years old).

If you take more Linezolid than you should

If you are concerned that you may have been given too much Linezolid, tell your doctor or a nurse at once.

If forget to take Linezolid

As you will be given this medicine under close supervision, it is very unlikely that you will miss a dose. If you think that you have missed a dose of treatment, tell a doctor or nurse at once.

4. Possible side effects

Like all medicines Linezolid can cause side-effects although not everybody gets them.

Tell your doctor, nurse or pharmacist immediately if you notice any of these side effects during your treatment with Linezolid:

•    skin reactions such as red sore skin and flaking (dermatitis), rash, itching, or swelling, particularly around the face and neck. This may be the sign of an allergic reaction and it may be necessary for you to stop taking Linezolid.

•    problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or if your field of vision becomes restricted.

•    severe diarrhoea containing blood and/or mucus (antibiotic associated colitis including pseudomembranous colitis), which in very rare circumstances may develop into complications that are life-threatening.

•    recurrent nausea or vomiting, abdominal pain or over breathing.

•    fits or seizures have been reported with Linezolid. You should let your doctor know if you experience agitation, confusion, delirium, rigidity, tremor, incoordination and seizure while also taking antidepressants known as SSRI’s (see section 2).

Numbness, tingling or blurred vision have been reported by patients who have been given Linezolid for more than 28 days. If you experience difficulties with your vision you should consult your doctor as soon as possible.

Adults


Other side effects include:

Common: may affect up to 1 in 10 people:

•    Fungal infections especially vaginal or oral “thrush”

•    Headache

•    Metallic taste in the mouth

•    Diarrhoea, nausea or vomiting

•    Changes in some blood test results including those measuring your kidney or liver function or blood sugar levels

•    Unexplained bleeding or bruising, which may be due to changes in the numbers of certain cells in the blood which may affect blood clotting or lead to anaemia

Uncommon: may affect up to 1 in 100 people;

•    Inflammation of the vagina or genital area in women

•    Changes in numbers of certain cells in the blood which may affect your ability to fight infection

•    Difficulty in sleeping

•    Dizziness, sensations such as tingling or feeling numb

•    Blurred vision

•    “Ringing” in the ears (tinnitus)

•    Increased blood pressure, inflammation of the veins

•    Indigestion, stomach pain, constipation

•    Dry or sore mouth, swollen, sore, or discoloured tongue

•    Skin rash

•    Pain at and around the place where the infusion (drip) was given

•    Inflammation of the veins (including where the infusion (drip) was given)

•    A need to urinate more often

•    Fever or chills, aches and pains

•    Feeling tired or thirsty

•    Inflammation of the pancreas

•    Increased sweating

•    Changes in proteins, salts or enzymes in the blood which measure kidney or liver function

•    Reduction in the numbers of cells in the blood which fight against infection.

Rare: may affect up to 1 in 1000 people;

•    Changes in heart rate (eg, increase rate)

•    Transient ischaemic attacks (temporary disturbance of blood flow to the brain causing shortterm symptoms such as loss of vision, leg and arm weakness, slurring of speech and loss of consciousness)

•    Kidney failure.

Not known: frequency cannot be estimated from the available data

•    Serotonin syndrome (symptoms include fast heart rate, confusion, abnormal sweating, hallucinations, involuntary movements chills and shivering)

•    Lactic acidosis (symptoms include recurrent nausea and vomiting, abdominal pain, overbreathing)

•    Severe skin disorders

•    Convulsions

•    Superficial tooth discolouration, removable with professional dental cleaning (manual descaling)

•    Alopecia (hair loss)

•    Hyponatraemia (low blood sodium levels)

•    Changes in colour vision, difficulty in seeing detail or if your field of vision becomes restricted

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme, Website: www.mhra.aov.uk/vellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

5.    How to store Linezolid

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.

This medicinal product does not require any special temperature storage conditions. Keep the bottle in the outer pouch or carton box in order to protect from light.

After opening: From a microbiological point of view, unless the method of opening precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

Do not use this medicine if you notice any visible particulate matter or if the solution is cloudy.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6.    Contents of the pack and other information What Linezolid contains

The active substance is linezolid. Each 1ml of solution contains 2 mg linezolid.

The other ingredients are glucose monohydrate (a type of sugar), sodium citrate (E331), citric acid monohydrate, hydrochloric acid 5N (E507) or sodium hydroxide 5N (E524) and water for injections.

What Linezolid looks like and contents of the pack

Linezolid is a clear, colourless to yellow solution for infusion.

Linezolid is packaged in carton boxes containing 300 ml polypropylene bottles. Packs of 1, 2, 5, 10, 20 and 25 bottles. Not all pack sizes may be marketed.

Marketing Authorisation Holder: Noridem Enterprises Limited, Evagorou and Makariou, Mitsi Building 3, Office 115, 1065 Nicosia, Cyprus.

Manufacturer: DEMO S.A., 21st km National Road Athens-Lamia, 14568 Krioneri, Athens, Greece.

This medicinal product is authorised in the Member States of the EEA under the following names:

Portugal:    Linezolid Demo

Greece:    ZETALID 2 mg/ml AiaAupa yia £v6o9Aspia syxuari

Spain:    Linezolid Demo 2 mg/ml solucion para perfusion

United Kingdom:    Linezolid    2 mg/ml solution for infusion

Germany:    Linezolid Demo 2 mg/ml Infusionslosung

This leaflet was last revised in 11/2014.

Infections

Dosage and route for twice daily administration

Duration of treatment

Nosocomial pneumonia

600 mg twice daily

10-14 Consecutive Days

Community acquired Pneumonia

Complicated skin and soft tissue infections

600 mg twice daily


Linezolid 2mg/ml solution for infusion

For further information, consult the Summary of Product Characteristics (SPC).

Dosage and Method of Administration

Linezolid should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist or an infectious diseases specialist. Patients who commence treatment on the parenteral formulation may be switched to either oral presentation when clinically indicated. In such circumstances, no dose adjustment is required as linezolid has an oral bioavailability of approximately 100 %. The solution for infusion should be administered over a period of 30 to 120 minutes. The recommended linezolid dosage should be administered twice daily.

Recommended dosage and duration for adults: The duration of treatment is dependent on the pathogen, the site of infection and its severity, and on the patient’s clinical response. The following recommendations for duration of therapy reflect those used in the clinical trials. Shorter treatment regimens may be suitable for some types of infection but have not been evaluated in clinical trials. The maximum treatment duration is 28 days. The safety and effectiveness of linezolid have not yet been established for treatment periods longer than 28 days. No increase in the recommended dosage or duration of treatment is required for infections associated with concurrent bacteraemia. The dose recommendation is as follows:

Children: There are insufficient data on the pharmacokinetics, safety and efficacy of linezolid in children and adolescents (< 18 years old) to establish dosage recommendations. Therefore, until further data are available, use of linezolid in this age group is not recommended.

Elderly patients: No dose adjustment is required.

Patients with renal insufficiency: No dose adjustment is required. Patients with severe renal insufficiency (i.e. CLCR < 30 ml/min): No dose adjustment is required. Due to the unknown clinical significance of higher exposure (up to 10-fold) to the two primary metabolites of linezolid in patients with severe renal insufficiency, linezolid should be used with special caution in these patients and only when the anticipated benefit is considered to outweigh the theoretical risk. As approximately 30 % of a linezolid dose is removed during 3 hours of haemodialysis, Linezolid should be given after dialysis in patients receiving such treatment. The primary metabolites of linezolid are removed to some extent by haemodialysis, but the concentrations of these metabolites are still very considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency. Therefore, linezolid should be used with special caution in patients with severe renal insufficiency who are undergoing dialysis, and only when the anticipated benefit is considered to outweigh the theoretical risk. To date, there is no experience of linezolid administration to patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or alternative treatments for renal failure (other than haemodialysis).

Patients with hepatic insufficiency: Patients with mild to moderate hepatic insufficiency (Child-Pugh class

A or B): No dose adjustment is required. Patients with severe hepatic insufficiency (Child-Pugh class C): As linezolid is metabolised by a nonenzymatic process, impairment of hepatic function would not be expected to significantly alter its metabolism and, therefore, no dose adjustment is recommended. However, there are no pharmacokinetic data and limited clinical experience of Linezolid in patients with severe hepatic insufficiency. Linezolid should be used with special caution in patients with severe hepatic insufficiency and only when the anticipated benefit is considered to outweigh the theoretical risk.

Instructions for Use and Handling

For single use only. The solution should be visually inspected prior to use and only clear solutions, without particles should be used. Any unused solution must be discarded. Linezolid Solution for Infusion is compatible with the following solutions: 5 % glucose intravenous infusion, 0.9 % sodium chloride intravenous infusion, Ringer-lactate solution for injection (Hartmann’s solution for injection).

Incompatibilities

Additives should not be introduced into this solution. If linezolid is to be given concomitantly with other drugs, each drug should be given separately in accordance with its own directions for use. Similarly, if the same intravenous line is to be used for sequential infusion of several drugs, the line should be flushed prior to and following linezolid administration with a compatible infusion solution. Linezolid is known to be physically incompatible with the following compounds: amphotericin B, chlorpromazine hydrochloride, diazepam, pentamidine isethionate, erythromycin lactobionate, phenytoin sodium and sulphamethoxazole / trimethoprim. Additionally, it is chemically incompatible with ceftriaxone sodium.

If this leaflet is difficult to see or read, please contact the following address for help:

Fannin Limited, Fannin House, South County Business Park,

Leopardstown, Dublin 18, Ireland Tel +353-1-2907000.